How can we predict bacterial eradication? (Q35168554)

6 August 2017

title

How can we predict bacterial eradication? (English)

1 reference

eradication of infectious diseases

6 August 2017

main subject

1 reference

Michael R Jacobs

1 reference

6 August 2017

publication date

1 March 2003

1 reference

International Journal of Infectious Diseases

6 August 2017

published in

1 reference

6 August 2017

volume

7 Suppl 1

1 reference

6 August 2017

page(s)

S13-20

1 reference

The hidden impact of antibacterial resistance in respiratory tract infection. Re-evaluating current antibiotic therapy

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990066-X

7 January 2021

How predictive is PK/PD for antibacterial agents?

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990066-X

7 January 2021

Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990066-X

7 January 2021

The role of newer macrolides in the treatment of community-acquired respiratory tract infection. A review of experimental and clinical data

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990066-X

7 January 2021

Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990066-X

7 January 2021

Animal model pharmacokinetics and pharmacodynamics: a critical review

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990066-X

7 January 2021

Antimicrobial resistance issues of the future

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990066-X

7 January 2021

Evidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990066-X

7 January 2021

Comparative efficacy of gemifloxacin in experimental models of pyelonephritis and wound infection

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990066-X

7 January 2021

Comparative in vivo activity of gemifloxacin in a rat model of respiratory tract infection

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990066-X

7 January 2021

Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990066-X

7 January 2021

Drug-resistant Streptococcus pneumoniae: rational antibiotic choices.

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990066-X

7 January 2021

Efficacy of high-dose amoxicillin-clavulanate against experimental respiratory tract infections caused by strains of Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990066-X

7 January 2021

The clinical pharmacokinetics of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2803%2990066-X

7 January 2021

10.1016/S1201-9712(03)90066-X

Identifiers

DOI

1 reference

6 August 2017

1 reference